Losartan for Diastolic Hypertension
Losartan is an appropriate first-line treatment for isolated diastolic hypertension in adults without contraindications, as ARBs are endorsed by the 2017 ACC/AHA guidelines as primary antihypertensive agents with proven cardiovascular benefit. 1
Treatment Decision Algorithm
Determine your treatment approach based on blood pressure stage and cardiovascular risk:
Diastolic BP 90-99 mmHg (Stage 1) with <10% 10-year ASCVD risk: Start with nonpharmacological therapy alone and reassess in 3-6 months 1
Diastolic BP 90-99 mmHg (Stage 1) with ≥10% 10-year ASCVD risk: Initiate losartan plus lifestyle modifications immediately 1
Diastolic BP ≥100 mmHg (Stage 2): Start combination therapy with two agents of different classes (losartan plus either a thiazide diuretic or calcium channel blocker) 1
Diastolic BP ≥110 mmHg: Prompt evaluation and immediate antihypertensive treatment required 1
Losartan Dosing and Titration
Starting dose: 50 mg once daily 1
Titration schedule:
- Reassess blood pressure in 1 month after initiation 1
- If BP not controlled, increase to 100 mg once daily 1
- If still uncontrolled on maximum losartan dose, add hydrochlorothiazide 12.5-25 mg daily 1, 2
The combination of losartan plus hydrochlorothiazide provides superior antihypertensive efficacy compared to monotherapy, with reductions in systolic BP of approximately 19-28 mmHg 2, 3, 4
Monitoring Parameters
Baseline assessment:
Follow-up monitoring:
- Recheck electrolytes and renal function 2-4 weeks after initiating losartan 1
- Monitor for hyperkalemia, especially in patients with chronic kidney disease or those on potassium supplements 1
- Assess for orthostatic hypotension in elderly patients 1
- Repeat BP evaluation in 1 month, then adjust therapy as needed 1
Blood Pressure Targets
Target diastolic BP <80 mmHg (with systolic <130 mmHg) for most adults if tolerated 5
Minimum acceptable target: <90 mmHg diastolic (with systolic <140 mmHg) 1
Alternative First-Line Options
When losartan is contraindicated or not tolerated, consider these guideline-endorsed alternatives:
- Thiazide diuretics (chlorthalidone 12.5-25 mg or hydrochlorothiazide 25-50 mg daily) - preferred based on proven cardiovascular outcome data 1, 5
- ACE inhibitors (e.g., lisinopril 10-40 mg daily) - equivalent efficacy to losartan 1, 5
- Dihydropyridine calcium channel blockers (e.g., amlodipine 5-10 mg daily) 1, 5
Losartan demonstrated superior outcomes compared to atenolol in patients with isolated systolic hypertension and left ventricular hypertrophy, reducing cardiovascular mortality by 46% (RR 0.54, p=0.01) and stroke by 40% (RR 0.60, p=0.02) 4. This suggests particular benefit in patients with target organ damage.
Critical Pitfalls to Avoid
Do not combine losartan with ACE inhibitors or direct renin inhibitors - this combination is potentially harmful and not recommended 1
Do not use beta-blockers as first-line monotherapy for uncomplicated diastolic hypertension, as they are less effective than thiazides, ARBs, ACE inhibitors, and calcium channel blockers for cardiovascular event reduction 5
Assess for bilateral renal artery stenosis before starting losartan, as ARBs can precipitate acute renal failure in this setting 1
Screen for pregnancy - losartan is contraindicated in pregnancy 1
Monitor for angioedema - though rare, this life-threatening adverse effect can occur with ARBs 6
Tolerability Advantages
Losartan is better tolerated than many alternatives, with lower withdrawal rates due to adverse events compared to captopril (11% vs 16%) and atenolol (10.4% vs 23% in isolated systolic hypertension) 2, 4. The overall adverse event rate with losartan (19-27%) is similar to calcium channel blockers but with better tolerability than ACE inhibitors 2. First-dose hypotension is uncommon due to the slower onset of action 6.